Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01927627 · ClinicalTrials.gov registry record · Phase 2
Enzalutamide in Patients With High-risk Prostate Cancer
A Phase 2 study of Adenocarcinoma of the Prostate, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT01927627: Completed Phase 2 study of Adenocarcinoma of the Prostate, sponsored by Case Comprehensive Cancer Center.
NCT01927627 is a Phase 2 study of Adenocarcinoma of the Prostate that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 42 participants, below the 108-participant average among 21 other Adenocarcinoma of the Prostate trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01927627, a Phase 2 study of Adenocarcinoma of the Prostate, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see how long it takes for prostate cancer to come back in patients who have had surgery to remove their prostate gland (radical prostatectomy), while being treated with enzalutamide (formerly known as MDV3100). Enzalutamide is known as an androgen-receptor signaling inhibitor, which means that it blocks activity of the male hormone, testosterone. Most prostate cancers are dependent on testosterone for growth. In this study, patients will take enzalutamide after surgery to see if it keeps their cancer from coming back.
Primary Outcome
Clinical efficacy is measured as time to disease progression defined by biochemical recurrence (BCR). BCR was defined as PSA ≥0.2ng/mL on 2 consecutive lab results or any PSA rise that resulted in subsequent therapy.
Conditions Studied
Interventions
- DRUG enzalutamide
Study Locations (1)
Ohio
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2013-11-11 |
| Est. Completion | 2017-04-26 |
| Phase | Phase 2 |
What the finished NCT01927627 record still lists
NCT01927627 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 108-participant average among 21 other Adenocarcinoma of the Prostate trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Adenocarcinoma of the Prostate appearing as the primary indexed condition, and to 1 intervention - of which enzalutamide is the first listed.
NCT01927627 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT01927627 about?
NCT01927627 is a clinical study titled "Enzalutamide in Patients With High-risk Prostate Cancer". The purpose of this study is to see how long it takes for prostate cancer to come back in patients who have had surgery to remove their prostate gland (radical prostatectomy), while being treated with enzalutamide (formerly known as MDV3100). Enzalutamide is known as an androgen-receptor signaling ...
What is the current status of trial NCT01927627?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2013-11-11. Estimated completion is 2017-04-26.
What conditions does trial NCT01927627 study?
This clinical trial studies the following conditions: Adenocarcinoma of the Prostate.
What interventions are being tested in trial NCT01927627?
The interventions under investigation include: enzalutamide (DRUG).
Who is sponsoring clinical trial NCT01927627?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01927627 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenocarcinoma of the Prostate
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01927627's enrollment target sits among peer trials
42 12th of 21 higher than 9 of 21 other Adenocarcinoma of the Prostate trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Adenocarcinoma of the Prostate trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery
COMPLETED · Phase 2
-
A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection
COMPLETED · Phase 2
-
Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer
COMPLETED · Phase 2
-
17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
COMPLETED · Phase 2
-
Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI